Trial Profile

A phase 1 clinical trial of ARC-706, and its companion diagnostic, ARC-166

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 28 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARC 166 (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

28 Jun 2025 New trial record
20 Jun 2025 According to a Archeus Technologies media release, the company received IND clearances in October 2024 for its lead therapeutic candidate, ARC-706, and companion diagnostic, ARC-166. The company plans to advance the two assets, together as a theranostic pair, into clinical development this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com